← Back to Screener
GeneDx Holdings Corp. Class A Common Stock (WGS)
Price$65.42
Favorite Metrics
Price vs S&P 500 (26W)-49.00%
Price vs S&P 500 (4W)-10.39%
Market Capitalization$1.98B
All Metrics
P/CF (Annual)59.37x
Book Value / Share (Quarterly)$10.54
P/TBV (Annual)26.91x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.13%
Cash Flow / Share (Quarterly)$0.49
Price vs S&P 500 (YTD)-50.77%
Gross Margin (TTM)69.74%
Net Profit Margin (TTM)-4.92%
EPS (TTM)$-0.74
10-Day Avg Trading Volume0.65M
EPS Excl Extra (TTM)$-0.74
Revenue Growth (5Y)18.98%
EPS (Annual)$-0.73
ROI (Annual)-5.55%
Gross Margin (Annual)69.74%
Net Profit Margin (5Y Avg)-91.68%
Cash / Share (Quarterly)$5.86
P/E Basic Excl Extra (TTM)1216.10x
Revenue Growth QoQ (YoY)26.50%
ROA (Last FY)-4.01%
Revenue Growth TTM (YoY)39.97%
EBITD / Share (TTM)$-0.18
ROE (5Y Avg)-76.97%
Operating Margin (TTM)-3.06%
Cash Flow / Share (Annual)$0.49
P/B Ratio6.41x
P/B Ratio (Quarterly)12.20x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.54x
Net Interest Coverage (TTM)-7.32x
ROA (TTM)-4.36%
EV / EBITDA (TTM)68.33x
EPS Incl Extra (Annual)$-0.73
Current Ratio (Annual)2.46x
Quick Ratio (Quarterly)2.27x
3-Month Avg Trading Volume0.68M
52-Week Price Return-33.23%
EV / Free Cash Flow (Annual)136.12x
P/E Incl Extra (TTM)1216.10x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.78
P/S Ratio (Annual)4.62x
Asset Turnover (Annual)0.82x
52-Week High$170.87
Operating Margin (5Y Avg)-119.21%
EPS Excl Extra (Annual)$-0.73
CapEx CAGR (5Y)-9.87%
26-Week Price Return-45.02%
Quick Ratio (Annual)2.27x
13-Week Price Return-43.42%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)2.46x
Enterprise Value$1,941.33
Revenue / Share Growth (5Y)-9.73%
Asset Turnover (TTM)0.89x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)10.52x
Pretax Margin (Annual)-4.94%
Cash / Share (Annual)$5.86
3-Month Return Std Dev79.87%
Gross Margin (5Y Avg)31.71%
Net Income / Employee (TTM)$-0
ROE (Last FY)-6.82%
Net Interest Coverage (Annual)-7.32x
EPS Basic Excl Extra (Annual)$-0.73
Receivables Turnover (TTM)7.65x
EV / Free Cash Flow (TTM)136.12x
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-0.74
Receivables Turnover (Annual)7.65x
ROI (TTM)-6.16%
P/S Ratio (TTM)4.62x
Pretax Margin (5Y Avg)-95.97%
Revenue / Share (Annual)$14.93
Tangible BV / Share (Annual)$4.78
Forward P/E82.55x
Price vs S&P 500 (52W)-63.06%
P/E Ratio (TTM)1216.10x
Year-to-Date Return-48.13%
5-Day Price Return12.34%
EPS Normalized (Annual)$-0.73
ROA (5Y Avg)-42.92%
Net Profit Margin (Annual)-4.92%
Month-to-Date Return5.05%
Cash Flow / Share (TTM)$-19.03
EBITD / Share (Annual)$-0.50
Operating Margin (Annual)-3.06%
LT Debt / Equity (Annual)0.16x
P/CF (TTM)59.37x
ROI (5Y Avg)-67.07%
P/E Excl Extra (TTM)1216.10x
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-0.74
P/TBV (Quarterly)26.91x
P/B Ratio (Annual)12.20x
Inventory Turnover (TTM)10.37x
Pretax Margin (TTM)-4.94%
Book Value / Share (Annual)$10.54
Price vs S&P 500 (13W)-44.11%
Beta2.23x
P/FCF (Annual)138.54x
Revenue / Share (TTM)$14.72
ROE (TTM)-7.41%
52-Week Low$55.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.23
4.23
Industry Peers — Health Services(13)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
WGSGeneDx Holdings Corp. Class A Common Stock | — | 39.97% | -3.06% | -7.41% | $65.42 |
PRVAPrivia Health Group, Inc. Common Stock | 126.50x | 22.26% | 1.61% | 3.29% | $23.50 |
LFSTLifeStance Health Group, Inc. Common Stock | 264.21x | -12.76% | 2.07% | 0.65% | $6.67 |
USPHUS Physical Therapy Inc | 29.52x | 16.33% | 11.08% | 8.00% | $78.18 |
INNVInnovAge Holding Corp. Common Stock | — | 13.48% | 1.01% | 2.66% | $8.37 |
PNTGThe Pennant Group, Inc. Common Stock | 35.79x | 36.31% | 5.47% | 9.31% | $30.42 |
TALKTalkspace, Inc. Common Stock | 110.84x | 22.00% | 1.38% | 6.89% | $5.17 |
OMDAOmada Health, Inc. Common Stock | — | — | -5.41% | -7.10% | $13.37 |
SRTAStrata Critical Medical, Inc. Class A Common Stock | 9.45x | -3.02% | -10.18% | 16.45% | $4.50 |
DCGODocGo Inc. Common Stock | 3.28x | -47.74% | -56.81% | -71.45% | $0.58 |
PIIIP3 Health Partners Inc. Common Stock | — | -2.76% | -18.53% | -191.97% | $2.50 |
About
GeneDx Holdings develops exome and genome sequencing technologies for diagnosing rare and ultra-rare pediatric genetic disorders. The company addresses a growing market opportunity as genetic testing becomes the standard diagnostic approach, enabling earlier diagnoses and improved patient outcomes. With a core business in pediatric and rare disease diagnostics, GeneDx is expanding into data and information services as precision medicine adoption accelerates.